Rheumatic fever is one of the complications associated with strep throat. It occurs as a delayed sequel to group A streptococcal pharyngitis. It may affect connective tissues of the joints, heart, vessels, and skin. In developing economies, rheumatic fever is highly prevalent and remains one of the major causes of acquired cardiovascular disease. Rheumatic fever is a major cause of mortality among people aged 50 years and above. According to the United Nations Department of Economic and Social Affairs, in 2015, the global population aged 60 years and above was approximately 901 million, and the number is expected to increase significantly during the forecast period. The population aged 50 years and above has a higher incidence of rheumatic disease and mortality rates as compared to younger people. The incidence rate of rheumatic fever is higher in developing countries as compared to that in developed countries. According to the Centers for Disease Control and Prevention (CDC), about 23% of adults in the U.S., which is over 54 million people, have arthritis. By 2040, the disease is expected to affect 78 million adults in the country. Rheumatic fever is a leading cause of disability. The direct medical costs associated with the disease are over US$ 81 Mn annually. This disease is more common in women than in men.
The global rheumatic fever treatment market can be segmented based on drug class, route of administration, distribution channel, and geography. Based on drug class, the global rheumatic fever treatment market can be classified into antibiotics, disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), anticonvulsant medication, and others. Antibiotics are a type of medicine that helps in arresting infections caused by bacteria. They prevent the spread of bacterial infections, either by killing the bacteria or by curtailing their ability to reproduce. Disease-modifying anti-rheumatic drugs (DMARDs) is a group of medicines or a combination of medicines used to treat a rheumatic fever by blocking inflammation. Disease-modifying anti-rheumatic drugs are categorized into two major types: biologic DMARDs and synthetic DMARDs (also called traditional DMARDs). The use of biologic DMARDs is higher. Nonsteroidal anti-inflammatory drugs (NSAIDs) is a class of analgesic drugs that reduce pain and inflammation by decreasing the blood level of prostaglandins. Prostaglandins are chemicals that promote inflammation and pain. Anticonvulsants are a diverse group of pharmacological agents used in the treatment of rheumatic fever. They are also increasingly being used in the treatment of rheumatic fever.
Based on the route of administration, the global rheumatic fever treatment market can be categorized into oral, parenteral, and topical. In terms of the distribution channel, the global rheumatic fever treatment market can be segmented into retail pharmacies, hospital pharmacies, and online pharmacies. Retail pharmacies are stores where drugs are dispensed to patients. A community retail pharmacy can be an independent pharmacy, a supermarket pharmacy, a chain pharmacy, or a mass merchandiser pharmacy with a state license to dispense medications to the general public at retail prices as a pharmacy. A hospital pharmacy is a department or service in a hospital that is responsible for the supply of medicines to hospital ward patients as well as ambulatory patients. An online pharmacy, Internet pharmacy, or mail-order pharmacy is a pharmacy that operates over the Internet and delivers orders to customers through shipping companies. An increase in the preference for online purchasing is expected to boost the online pharmacies segment during the forecast period.
Based on geography, the rheumatic fever treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The rheumatic fever treatment market in North America can be segmented into the U.S. and Canada. The rheumatic fever treatment market in Europe can be segmented into the U.K., Germany, France, Italy, Spain, and Rest of Europe. The rheumatic fever treatment market in the Asia Pacific can be further segmented into China, Japan, India, Australia & New Zealand, and Rest of Asia Pacific. The rheumatic fever treatment market in Latin America can be classified into Mexico, Brazil, and Rest of Latin America. The rheumatic fever treatment market in Middle East & Africa can be segmented into South Africa, Saudi Arabia, Israel, and Rest of Middle East & Africa. North America dominated the global rheumatic fever treatment market, owing to an increase in the geriatric population and a rise in the prevalence of rheumatic fever in the region.
Some of the major players in global rheumatic fever treatment market are Abbott, F. Hoffmann-La Roche Ltd, Novartis, Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Bayer AG, and Bausch Health Companies Inc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- The Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates are included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.